A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT ID: NCT07063745
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2/PHASE3
590 participants
INTERVENTIONAL
2025-11-28
2031-08-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
The Phase 3 portion of this study will be blinded to participants, investigators, and the Sponsor.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A: BMS-986504 + Pembrolizumab + Chemotherapy
BMS-986504
Specified dose on specified days
Pembrolizumab
Specified dose on specified days
Cisplatin
Specified dose on specified days
Carboplatin
Specified dose on specified days
Pemetrexed
Specified dose on specified days
Paclitaxel
Specified dose on specified days
Nab-paclitaxel
Specified dose on specified days
Arm B: BMS-986504 + Pembrolizumab + Chemotherapy
BMS-986504
Specified dose on specified days
Pembrolizumab
Specified dose on specified days
Cisplatin
Specified dose on specified days
Carboplatin
Specified dose on specified days
Pemetrexed
Specified dose on specified days
Paclitaxel
Specified dose on specified days
Nab-paclitaxel
Specified dose on specified days
Arm C: Placebo + Pembrolizumab + Chemotherapy
Pembrolizumab
Specified dose on specified days
Placebo
Specified dose on specified days
Cisplatin
Specified dose on specified days
Carboplatin
Specified dose on specified days
Pemetrexed
Specified dose on specified days
Paclitaxel
Specified dose on specified days
Nab-paclitaxel
Specified dose on specified days
Arm D: Placebo + Pembrolizumab + Chemotherapy
Pembrolizumab
Specified dose on specified days
Placebo
Specified dose on specified days
Cisplatin
Specified dose on specified days
Carboplatin
Specified dose on specified days
Pemetrexed
Specified dose on specified days
Paclitaxel
Specified dose on specified days
Nab-paclitaxel
Specified dose on specified days
Arm E: BMS-986504 + Pembrolizumab + Chemotherapy
BMS-986504
Specified dose on specified days
Pembrolizumab
Specified dose on specified days
Cisplatin
Specified dose on specified days
Carboplatin
Specified dose on specified days
Pemetrexed
Specified dose on specified days
Paclitaxel
Specified dose on specified days
Nab-paclitaxel
Specified dose on specified days
Arm F: Placebo + Pembrolizumab + Chemotherapy
Pembrolizumab
Specified dose on specified days
Placebo
Specified dose on specified days
Cisplatin
Specified dose on specified days
Carboplatin
Specified dose on specified days
Pemetrexed
Specified dose on specified days
Paclitaxel
Specified dose on specified days
Nab-paclitaxel
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986504
Specified dose on specified days
Pembrolizumab
Specified dose on specified days
Placebo
Specified dose on specified days
Cisplatin
Specified dose on specified days
Carboplatin
Specified dose on specified days
Pemetrexed
Specified dose on specified days
Paclitaxel
Specified dose on specified days
Nab-paclitaxel
Specified dose on specified days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must have histologically confirmed diagnosis of NSCLC and homozygous methylthioadenosine phosphorylase (MTAP) deletion or MTAP loss.
* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
* Participants must have at least 1 measurable lesion as per RECIST v1.1.
Exclusion Criteria
* Participants must not have symptomatic brain metastases or spinal cord compression.
* Participants must not have any prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for metastatic non-small cell lung cancer (mNSCLC). Note: One cycle of SoC treatment prior to randomization will be allowed for participants who require immediate treatment if clinically indicated.
* Participants must not have any known or suspected impairment of gastrointestinal function that may prohibit the ability to absorb or swallow an oral medication without chewing or crushing.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alaska Oncology and Hematology
Anchorage, Alaska, United States
Local Institution - 0388
Phoenix, Arizona, United States
Local Institution - 0120
Tucson, Arizona, United States
Highlands Oncology Group
Springdale, Arkansas, United States
Local Institution - 0407
Los Angeles, California, United States
Local Institution - 0444
Los Angeles, California, United States
Local Institution - 0152
Fort Lauderdale, Florida, United States
Local Institution - 0389
Jacksonville, Florida, United States
Local Institution - 0430
St. Petersburg, Florida, United States
St. Luke's Cancer Institute: Boise
Boise, Idaho, United States
Local Institution - 0333
Lexington, Kentucky, United States
Local Institution - 0125
Lexington, Kentucky, United States
Local Institution - 0127
Scarborough, Maine, United States
Local Institution - 0158
Boston, Massachusetts, United States
Local Institution - 0418
Ann Arbor, Michigan, United States
Local Institution - 0405
Detroit, Michigan, United States
Local Institution - 0420
Traverse City, Michigan, United States
Local Institution - 0182
Rochester, Minnesota, United States
Oncology Hematology West P.C. dba Nebraska Cancer Specialists
Omaha, Nebraska, United States
Local Institution - 0179
Hawthorne, New York, United States
Local Institution - 0128
Rochester, New York, United States
Local Institution - 0163
Cleveland, Ohio, United States
Local Institution - 0129
Columbus, Ohio, United States
Local Institution - 0164
Portland, Oregon, United States
Local Institution - 0348
Portland, Oregon, United States
Local Institution - 0433
Dallas, Texas, United States
Local Institution - 0374
El Paso, Texas, United States
Local Institution - 0132
Houston, Texas, United States
Local Institution - 0377
The Woodlands, Texas, United States
Local Institution - 0354
Salt Lake City, Utah, United States
Local Institution - 0131
Fairfax, Virginia, United States
Local Institution - 0186
Richmond, Virginia, United States
Local Institution - 0145
Seattle, Washington, United States
Local Institution - 0463
Rosario, Santa Fe Province, Argentina
Local Institution - 0447
Buenos Aires, , Argentina
Local Institution - 0446
Buenos Aires, , Argentina
Local Institution - 0432
Liverpool, New South Wales, Australia
Local Institution - 0382
Birtinya, Queensland, Australia
Local Institution - 0381
Elizabeth Vale, South Australia, Australia
Local Institution - 0431
Hobart, Tasmania, Australia
Local Institution - 0367
Ballarat Central, Victoria, Australia
Local Institution - 0368
Garran, , Australia
Local Institution - 0373
Woolloongabba, , Australia
Local Institution - 0207
Vienna, , Austria
Local Institution - 0227
Edegem, Antwerpen, Belgium
Local Institution - 0226
Hasselt, Limburg, Belgium
Local Institution - 0225
Yvoir, Namur, Belgium
Local Institution - 0277
Roeselare, West-Vlaanderen, Belgium
Local Institution - 0342
Brussels, , Belgium
Local Institution - 0340
Liège, , Belgium
Local Institution - 0088
Vitória, Espírito Santo, Brazil
Local Institution - 0079
Natal, Rio Grande do Norte, Brazil
Local Institution - 0346
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 0085
Blumenau, Santa Catarina, Brazil
Local Institution - 0081
Barretos, São Paulo, Brazil
Local Institution - 0076
Bauru, São Paulo, Brazil
Local Institution - 0094
Campinas, São Paulo, Brazil
Local Institution - 0355
São Caetano do Sul, São Paulo, Brazil
Local Institution - 0351
São José do Rio Preto, São Paulo, Brazil
Local Institution - 0095
São Paulo, São Paulo, Brazil
Local Institution - 0091
Rio de Janeiro, , Brazil
Local Institution - 0078
São Paulo, , Brazil
Local Institution - 0315
Panagyurishte, Pazardzhik, Bulgaria
Local Institution - 0459
Sofia, Sofia, Bulgaria
Local Institution - 0309
Haskovo, , Bulgaria
Local Institution - 0308
Rousse, , Bulgaria
Local Institution - 0460
Sofia, , Bulgaria
Local Institution - 0307
Stara Zagora, , Bulgaria
Local Institution - 0072
Hefei, Anhui, China
Local Institution - 0074
Beijing, Beijing Municipality, China
Local Institution - 0049
Beijing, Beijing Municipality, China
Local Institution - 0286
Beijing, Beijing Municipality, China
Local Institution - 0046
Fuzhou, Fujian, China
Local Institution - 0100
Xiamen, Fujian, China
Local Institution - 0099
Guangzhou, Guangdong, China
Local Institution - 0443
Guangzhou, Guangdong, China
Local Institution - 0061
Guangzhou, Guangdong, China
Local Institution - 0281
Shenzhen, Guangdong, China
Local Institution - 0067
Nanning, Guangxi, China
Local Institution - 0408
Guiyang, Guizhou, China
Local Institution - 0353
Shijiazhuang, Hebei, China
Local Institution - 0106
Harbin, Heilongjiang, China
Local Institution - 0107
Zhengzhou, Henan, China
Local Institution - 0048
Wuhan, Hubei, China
Local Institution - 0059
Wuhan, Hubei, China
Local Institution - 0387
Changsha, Hunan, China
Local Institution - 0050
Changsha, Hunan, China
Local Institution - 0352
Nanjing, Jiangsu, China
Local Institution - 0279
Nanjing, Jiangsu, China
Local Institution - 0110
Nanchang, Jiangxi, China
Local Institution - 0284
Shenyang, Liaoning, China
Local Institution - 0104
Shenyang, Liaoning, China
Local Institution - 0103
Shenyang, Liaoning, China
Local Institution - 0060
Xi'an, Shaanxi, China
Local Institution - 0051
Jinan, Shandong, China
Local Institution - 0066
Linyi, Shandong, China
Local Institution - 0068
Qingdao, Shandong, China
Local Institution - 0278
Shanghai, Shanghai Municipality, China
Local Institution - 0343
Shanghai, Shanghai Municipality, China
Local Institution - 0283
Taiyuan, Shanxi, China
Local Institution - 0102
Chengdu, Sichuan, China
Local Institution - 0109
Chengdu, Sichuan, China
Local Institution - 0280
Hangzhou, Zhejiang, China
Local Institution - 0069
Hangzhou, Zhejiang, China
Local Institution - 0054
Hangzhou, Zhejiang, China
Local Institution - 0386
Nanjing, , China
Local Institution - 0047
Zhengzhou, , China
Local Institution - 0330
Medellín, Antioquia, Colombia
Local Institution - 0305
Bogotá, Cundinamarca, Colombia
Local Institution - 0306
Montería, Departamento de Córdoba, Colombia
Local Institution - 0251
Hradec Králové, Hradec Králové, Czechia
Local Institution - 0250
Olomouc, , Czechia
Local Institution - 0356
Copenhagen, Capital Region, Denmark
Local Institution - 0219
Pessac, Aquitaine, France
Local Institution - 0217
Caen, Calvados, France
Local Institution - 0212
Dijon, Côte-d'Or, France
Local Institution - 0341
Besançon, Doubs, France
Local Institution - 0221
Brest, Finistère, France
Local Institution - 0216
Toulouse, Haute-Garonne, France
Local Institution - 0220
Montpellier, Hérault, France
Local Institution - 0222
Rennes, Ille-et-Vilaine, France
Local Institution - 0215
Saint-Herblain, Loire-Atlantique, France
Local Institution - 0211
Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France
Local Institution - 0224
Marseille, Provence-Alpes-Côte d'Azur Region, France
Local Institution - 0223
Clermont-Ferrand, Puy-de-Dôme, France
Local Institution - 0214
Pierre-Bénite, Rhône, France
Local Institution - 0213
Créteil, Val-de-Marne, France
Local Institution - 0429
Paris, , France
Local Institution - 0218
Paris, , France
Local Institution - 0338
Tours, , France
Local Institution - 0202
München, Bavaria, Germany
Local Institution - 0209
Regensburg, Bavaria, Germany
Local Institution - 0008
Pátrai, Achaḯa, Greece
Local Institution - 0005
Athens, Attikí, Greece
Local Institution - 0001
Athens, Attikí, Greece
Local Institution - 0009
Athens, Attikí, Greece
Local Institution - 0006
Thessaloniki, Kentrikí Makedonía, Greece
Local Institution - 0003
Larissa, Thessalía, Greece
Local Institution - 0285
Hksar, , Hong Kong
Local Institution - 0323
Shatin, , Hong Kong
Local Institution - 0290
Gyula, Bekes County, Hungary
Local Institution - 0291
Gyöngyös, Heves County, Hungary
Local Institution - 0287
Farkasgyepű, Veszprém megye, Hungary
Local Institution - 0288
Budapest, , Hungary
Local Institution - 0263
Bangalore, Karnataka, India
Local Institution - 0344
Bengaluru, Karnataka, India
Local Institution - 0345
Mumbai, Maharashtra, India
Local Institution - 0266
Mumbai, Maharashtra, India
Local Institution - 0267
New Delhi, National Capital Territory of Delhi, India
Local Institution - 0265
Hyderabad, Telangana, India
Local Institution - 0264
Varanasi, Uttar Pradesh, India
Local Institution - 0010
Kfar Saba, Central District, Israel
Local Institution - 0011
Ramat Gan, Central District, Israel
Local Institution - 0017
Jerusalem, Jerusalem, Israel
Local Institution - 0013
Jerusalem, Jerusalem, Israel
Local Institution - 0016
Afula, Northern District, Israel
Local Institution - 0014
Haifa, Northern District, Israel
Local Institution - 0105
Napoli, Campania, Italy
Local Institution - 0042
Aviano, Friuli Venezia Giulia, Italy
Local Institution - 0037
Orbassano, Torino, Italy
Local Institution - 0044
Perugia, Umbria, Italy
Local Institution - 0098
Bologna, , Italy
Local Institution - 0039
Milan, , Italy
Local Institution - 0045
Milan, , Italy
Local Institution - 0035
Ravenna, , Italy
Local Institution - 0243
Nagoya, Aichi-ken, Japan
Local Institution - 0236
Kashiwa, Chiba, Japan
Local Institution - 0334
Otashi, Gunma, Japan
Local Institution - 0233
Sapporo, Hokkaido, Japan
Local Institution - 0336
Himeji, Hyōgo, Japan
Local Institution - 0247
Kobe, Hyōgo, Japan
Local Institution - 0335
Shiwa-gun Yahaba-cho, Iwate, Japan
Local Institution - 0257
Kawasaki, Kanagawa, Japan
Local Institution - 0238
Yokohama, Kanagawa, Japan
Local Institution - 0241
Nankoku, Kochi, Japan
Local Institution - 0237
Matsusaka, Mie-ken, Japan
Local Institution - 0232
Sendai, Miyagi, Japan
Local Institution - 0240
Hirakata, Osaka, Japan
Local Institution - 0245
Hidaka, Saitama, Japan
Local Institution - 0235
Shimotsuga, Tochigi, Japan
Local Institution - 0234
Bunkyo-ku, Tokyo, Japan
Local Institution - 0242
Ube, Yamaguchi, Japan
Local Institution - 0246
Fukuoka, , Japan
Local Institution - 0244
Okayama, , Japan
Local Institution - 0239
Osaka, , Japan
Local Institution - 0413
Kuala Lumpur, Kuala Lumpur, Malaysia
Local Institution - 0390
Kuching, Sarawak, Malaysia
Local Institution - 0296
Guadalajara, Jalisco, Mexico
Local Institution - 0326
Guadalajara, Jalisco, Mexico
Local Institution - 0293
Mexico City, Mexico City, Mexico
Local Institution - 0294
Mexico City, Mexico City, Mexico
Local Institution - 0298
Monterrey, Nuevo León, Mexico
Local Institution - 0297
Oaxaca City, Oaxaca, Mexico
Local Institution - 0328
Querétaro City, Querétaro, Mexico
Local Institution - 0327
Chihuahua City, , Mexico
Local Institution - 0331
Puebla City, , Mexico
Local Institution - 0445
Veldhoven, North Brabant, Netherlands
Local Institution - 0230
Arnhem, , Netherlands
Local Institution - 0249
Groningen, , Netherlands
Local Institution - 0096
Drammen, Buskerud, Norway
Local Institution - 0262
Poznan, Greater Poland Voivodeship, Poland
Local Institution - 0259
Krakow, Lesser Poland Voivodeship, Poland
Local Institution - 0261
Warsaw, Masovian Voivodeship, Poland
Local Institution - 0458
Wieliszew, Masovian Voivodeship, Poland
Local Institution - 0258
Prabuty, Pomeranian Voivodeship, Poland
Local Institution - 0260
Bydgoszcz, , Poland
Local Institution - 0021
Bucharest, București, Romania
Local Institution - 0019
Florești, Cluj, Romania
Local Institution - 0025
Craiova, Dolj, Romania
Local Institution - 0027
Otopeni, Ilfov, Romania
Local Institution - 0020
Bucharest, , Romania
Local Institution - 0022
Cluj-Napoca, , Romania
Local Institution - 0023
Cluj-Napoca, , Romania
Local Institution - 0031
Iași, , Romania
Local Institution - 0026
Iași, , Romania
Local Institution - 0030
Ploieşti, , Romania
Local Institution - 0272
Cheongju-si, Chungcheongbuk-do [Chungbuk], South Korea
Local Institution - 0271
Goyang-si, Kyǒnggi-do, South Korea
Local Institution - 0273
Seongnam, Kyǒnggi-do, South Korea
Local Institution - 0270
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Local Institution - 0269
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Local Institution - 0268
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Local Institution - 0274
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Local Institution - 0116
Barcelona, Barcelona [Barcelona], Spain
Local Institution - 0248
Hospitalet, Barcelona [Barcelona], Spain
Local Institution - 0253
Barcelona, Catalunya [Cataluña], Spain
Local Institution - 0118
Madrid, Madrid, Comunidad de, Spain
Local Institution - 0254
Madrid, Madrid, Comunidad de, Spain
Local Institution - 0252
Majadahonda, Madrid, Comunidad de, Spain
Local Institution - 0117
Málaga, , Spain
Local Institution - 0256
Seville, , Spain
Local Institution - 0255
Valencia, , Spain
Chi Mei Medical Center Liouying Branch
Tainan, Tainan, Taiwan
Local Institution - 0111
Tainan, , Taiwan
Local Institution - 0113
Taipei, , Taiwan
Taipei Medical University Hospital
Taipei, , Taiwan
Local Institution - 0112
Taoyuan District, , Taiwan
Local Institution - 0411
Bangkok, , Thailand
Local Institution - 0412
Bangkok, , Thailand
Local Institution - 0349
Izmir, Karsiyaka, İzmir, Turkey (Türkiye)
Local Institution - 0318
Adana, , Turkey (Türkiye)
Local Institution - 0317
Adana, , Turkey (Türkiye)
Local Institution - 0321
Ankara, , Turkey (Türkiye)
Local Institution - 0350
Antalya, , Turkey (Türkiye)
Local Institution - 0320
Bursa, , Turkey (Türkiye)
Local Institution - 0319
Edirne, , Turkey (Türkiye)
Local Institution - 0228
London, London, City of, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Role: CONTACT
Phone: 8559073286
Email: [email protected]
First line of the email MUST contain the NCT# and Site#
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Steven Liu, Site 0119
Role: primary
Site 0388
Role: primary
Site 0120
Role: primary
Eric Schaefer, Site 0135
Role: primary
Site 0407
Role: primary
Site 0444
Role: primary
Site 0152
Role: primary
Site 0389
Role: primary
Peyman Haghighat, Site 0124
Role: primary
Site 0333
Role: primary
Site 0125
Role: primary
Site 0127
Role: primary
Site 0158
Role: primary
Site 0418
Role: primary
Site 0405
Role: primary
Site 0420
Role: primary
Site 0182
Role: primary
Geetha Palaniappan, Site 0160
Role: primary
Site 0179
Role: primary
Site 0128
Role: primary
Site 0163
Role: primary
Site 0129
Role: primary
Site 0164
Role: primary
Site 0348
Role: primary
Site 0433
Role: primary
Site 0374
Role: primary
Site 0132
Role: primary
Site 0354
Role: primary
Site 0186
Role: primary
Site 0145
Role: primary
Site 0463
Role: primary
Site 0447
Role: primary
Site 0446
Role: primary
Site 0432
Role: primary
Site 0382
Role: primary
Site 0381
Role: primary
Site 0431
Role: primary
Site 0367
Role: primary
Site 0368
Role: primary
Site 0373
Role: primary
Site 0207
Role: primary
Site 0227
Role: primary
Site 0226
Role: primary
Site 0225
Role: primary
Site 0277
Role: primary
Site 0342
Role: primary
Site 0340
Role: primary
Site 0088
Role: primary
Site 0079
Role: primary
Site 0346
Role: primary
Site 0085
Role: primary
Site 0081
Role: primary
Site 0076
Role: primary
Site 0094
Role: primary
Site 0355
Role: primary
Site 0351
Role: primary
Site 0095
Role: primary
Site 0091
Role: primary
Site 0078
Role: primary
Site 0315
Role: primary
Site 0459
Role: primary
Site 0309
Role: primary
Site 0308
Role: primary
Site 0460
Role: primary
Site 0307
Role: primary
Site 0072
Role: primary
Site 0074
Role: primary
Site 0049
Role: primary
Site 0286
Role: primary
Site 0046
Role: primary
Site 0100
Role: primary
Site 0099
Role: primary
Site 0443
Role: primary
Site 0061
Role: primary
Site 0281
Role: primary
Site 0067
Role: primary
Site 0408
Role: primary
Site 0353
Role: primary
Site 0106
Role: primary
Site 0107
Role: primary
Site 0048
Role: primary
Site 0059
Role: primary
Site 0387
Role: primary
Site 0050
Role: primary
Site 0352
Role: primary
Site 0279
Role: primary
Site 0110
Role: primary
Site 0284
Role: primary
Site 0104
Role: primary
Site 0103
Role: primary
Site 0060
Role: primary
Site 0051
Role: primary
Site 0066
Role: primary
Site 0068
Role: primary
Site 0278
Role: primary
Site 0343
Role: primary
Site 0283
Role: primary
Site 0102
Role: primary
Site 0109
Role: primary
Site 0280
Role: primary
Site 0069
Role: primary
Site 0054
Role: primary
Site 0386
Role: primary
Site 0047
Role: primary
Site 0330
Role: primary
Site 0305
Role: primary
Site 0306
Role: primary
Site 0251
Role: primary
Site 0250
Role: primary
Site 0356
Role: primary
Site 0219
Role: primary
Site 0217
Role: primary
Site 0212
Role: primary
Site 0341
Role: primary
Site 0221
Role: primary
Site 0216
Role: primary
Site 0220
Role: primary
Site 0222
Role: primary
Site 0215
Role: primary
Site 0211
Role: primary
Site 0224
Role: primary
Site 0223
Role: primary
Site 0214
Role: primary
Site 0213
Role: primary
Site 0429
Role: primary
Site 0218
Role: primary
Site 0338
Role: primary
Site 0202
Role: primary
Site 0209
Role: primary
Site 0008
Role: primary
Site 0005
Role: primary
Site 0001
Role: primary
Site 0009
Role: primary
Site 0006
Role: primary
Site 0003
Role: primary
Site 0285
Role: primary
Site 0323
Role: primary
Site 0290
Role: primary
Site 0291
Role: primary
Site 0287
Role: primary
Site 0288
Role: primary
Site 0263
Role: primary
Site 0344
Role: primary
Site 0345
Role: primary
Site 0266
Role: primary
Site 0267
Role: primary
Site 0265
Role: primary
Site 0264
Role: primary
Site 0010
Role: primary
Site 0011
Role: primary
Site 0017
Role: primary
Site 0013
Role: primary
Site 0016
Role: primary
Site 0014
Role: primary
Site 0105
Role: primary
Site 0042
Role: primary
Site 0037
Role: primary
Site 0044
Role: primary
Site 0098
Role: primary
Site 0039
Role: primary
Site 0045
Role: primary
Site 0035
Role: primary
Site 0243
Role: primary
Site 0236
Role: primary
Site 0334
Role: primary
Site 0233
Role: primary
Site 0336
Role: primary
Site 0247
Role: primary
Site 0335
Role: primary
Site 0257
Role: primary
Site 0238
Role: primary
Site 0241
Role: primary
Site 0237
Role: primary
Site 0232
Role: primary
Site 0240
Role: primary
Site 0245
Role: primary
Site 0235
Role: primary
Site 0234
Role: primary
Site 0242
Role: primary
Site 0246
Role: primary
Site 0244
Role: primary
Site 0239
Role: primary
Site 0413
Role: primary
Site 0390
Role: primary
Site 0296
Role: primary
Site 0326
Role: primary
Site 0293
Role: primary
Site 0298
Role: primary
Site 0297
Role: primary
Site 0328
Role: primary
Site 0327
Role: primary
Site 0331
Role: primary
Site 0445
Role: primary
Site 0249
Role: primary
Site 0096
Role: primary
Site 0262
Role: primary
Site 0259
Role: primary
Site 0261
Role: primary
Site 0458
Role: primary
Site 0258
Role: primary
Site 0260
Role: primary
Site 0021
Role: primary
Site 0019
Role: primary
Site 0025
Role: primary
Site 0027
Role: primary
Site 0020
Role: primary
Site 0022
Role: primary
Site 0023
Role: primary
Site 0031
Role: primary
Site 0026
Role: primary
Site 0030
Role: primary
Site 0272
Role: primary
Site 0271
Role: primary
Site 0273
Role: primary
Site 0270
Role: primary
Site 0269
Role: primary
Site 0268
Role: primary
Site 0274
Role: primary
Site 0116
Role: primary
Site 0248
Role: primary
Site 0118
Role: primary
Site 0254
Role: primary
Site 0252
Role: primary
Site 0117
Role: primary
Site 0256
Role: primary
Site 0255
Role: primary
Cheng-Yao Lin, Site 0114
Role: primary
Site 0111
Role: primary
Site 0113
Role: primary
Chao-Hua Chiu, Site 0115
Role: primary
Site 0112
Role: primary
Site 0411
Role: primary
Site 0412
Role: primary
Site 0349
Role: primary
Site 0318
Role: primary
Site 0317
Role: primary
Site 0321
Role: primary
Site 0350
Role: primary
Site 0320
Role: primary
Site 0319
Role: primary
Site 0228
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-521511-40
Identifier Type: OTHER
Identifier Source: secondary_id
U1111-1319-8383
Identifier Type: OTHER
Identifier Source: secondary_id
CA2400029
Identifier Type: OTHER
Identifier Source: secondary_id
CA240-0029
Identifier Type: -
Identifier Source: org_study_id